Eyeworld

by Title ASCRS NEWS Heading Name title Contact Name: email ASCRS FOUNDATION UPDATE 18 | EYEWORLD | FALL 2024 ASCRS Foundation promotes efforts of Health in Sight Mission The ASCRS Foundation's mission is to educate, provide resources to, and empower the eye health community to serve and deliver humanitarian ophthalmic surgery and care in the U.S. and internationally. The ASCRS Foundation has supported many international programs and remains committed to its philanthropic priorities of humanitarian cataract and ophthalmic surgery, education, and training. In this issue's column, the ASCRS Foundation is spotlighting an outreach program dedicated to building self-sustaining care systems for underserved communities. Health in Sight Mission (HISM), led by board-certified oph- thalmologist Darin Bowers, MD, his wife, Pam Bowers, and Paul Kang, MD, a leading cataract and refractive surgeon, was formed in 2005 to serve the people of Roatán, Hondu- ras—the country with the lowest cataract surgery rate in Latin America. On their first trip to Roatán, HISM's team of volunteers screened hundreds of people, many of whom re- quired treatment for cataracts. Surgical care on the island began months later, followed by efforts to provide regular care at the local clinic. Today, the outreach of HISM has grown remarkably, now including oculoplastics, cornea, and the treatment of vitreoretinal disease. By collaborating with numerous eyecare professional volunteers, building long-term rela- tionships with local government and healthcare community members, and partnering with industry sponsors, HISM has treated more than 5,000 patients of all ages. But there is more work to be done to reach the overall goal of estab- lishing an independent clinic in Honduras fully staffed by local physicians. Medical care is only one part of their model for self-sustainability; volunteers work closely with the local government and healthcare communities to best meet area needs while enabling long-term success, and they rely on industry partnerships to enable the best care for local patients. After nearly 20 years since the first trip to Roatán, HISM remains committed to serving the people of Hondu- ras and other areas that could benefit from its self-support- ing care model. The ASCRS Foundation is proud to high- light the important work of organizations like HISM. How you can get involved with HISM Equipment and financial donations: HISM's current needs include an SLT laser for glaucoma patients, where there is limited access to medication and regular follow-up care, and a YAG laser for cataract patients. Advanced News from the ASCRS Foundation © 2024 Alcon Inc. 02/24 US-HDM-2400023 IMPORTANT PRODUCT INFORMATION CAUTION: Federal law restricts this device to sale by or on the order of a physician. INDICATIONS FOR USE: The Hydrus Microstent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: The Hydrus Microstent is contraindicated under the following circumstances or conditions: (1) In eyes with angle closure glaucoma; and (2) In eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber (AC) angle. WARNINGS: Clear media for adequate visualization is required. Conditions such as corneal haze, corneal opacity or other conditions may inhibit gonioscopic view of the intended implant location. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, peripheral anterior synechiae (PAS), angle closure, rubeosis and any other angle abnormalities that could lead to improper placement of the stent and pose a hazard. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The surgeon should periodically monitor the status of the microstent with gonioscopy to assess for the development of PAS, obstruction of the inlet, migration, or device-iris or device-cornea touch. The Hydrus Microstent is intended for implantation in conjunction with cataract surgery, which may impact corneal health. Therefore, caution is indicated in eyes with evidence of corneal compromise or with risk factors for corneal compromise following cataract surgery. Prior to implantation, patients with history of allergic reactions to nitinol, nickel or titanium should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials. PRECAUTIONS: If excessive resistance is encountered during the insertion of the microstent at any time during the procedure, discontinue use of the device. The safety and effectiveness of use of more than a single Hydrus Microstent has not been established. The safety and effectiveness of the Hydrus Microstent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, eyes with significant prior trauma, eyes with abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, eyes with preexisting pseudophakia, eyes with pseudoexfoliative or pigmentary glaucoma, and when implantation is without concomitant cataract surgery with IOL implantation. Please see a complete list of Precautions in the Instructions for use. ADVERSE EVENTS: The most frequently reported finding in the randomized pivotal trial was peripheral anterior synechiae (PAS), with the cumulative rate at 5 years (14.6% vs 3.7% for cataract surgery alone). Other Hydrus postoperative adverse events reported at 5 years included partial or complete device obstruction (8.4%) and device malposition (1.4%). Additionally, there were no new reports of persistent anterior uveitis (2/369, 0.5% at 2 years) from 2 to 5 years postoperative. There were no reports of explanted Hydrus implants over the 5-year follow-up. For additional adverse event information, please refer to the Instructions for Use. MRI INFORMATION: The Hydrus Microstent is MR- Conditional meaning that the device is safe for use in a specified MR environment under specified conditions. Please see the Instructions for Use for complete product information.

• Cover